The investigation focuses on specific procurement hurdles Cellebrite faced while pursuing government opportunities. According to the firm, these challenges were tied to the company's foreign-entity status, which introduced complex administrative requirements that may have been downplayed in previous public statements. Ademi LLP is currently scrutinizing whether these operational risks were adequately communicated to the market.

Shareholders who held stock during the period in question are being encouraged to come forward as the firm assesses the potential for litigation. The investigation covers the accuracy of Cellebrite’s reported business prospects and financial standing, specifically regarding its ability to execute on high-stakes government tenders.